Xavier Health has launched the Xavier Health Artificial Intelligence Initiative to help FDA and industry advance its predictive and prescriptive capabilities.
The official announcement of the new Artificial Intelligence Initiative was made by John Daley, Vice President, Quality and Regulatory Affairs, IBM Watson Health, and Marla Phillips, director of Xavier Health, at Xavier Health’s annual pharmaceutical conference, PharmaLink, March 15, 2017.
Partnering with IBM Watson Health, the mission of the initiative is to advance the pharmaceutical and medical device industries by augmenting human decisions with applied artificial intelligence, such that decisions move from reactive to predictive, thus increasing patient safety and business operation effectiveness.
The Center hopes to create AI solutions that can be implemented across quality, regulatory affairs and supply chain operations. The output of its work could be applied by data scientists within each organization, by consultants, or by solution providers.